{"schema_version":"secwatch.filing_event.v1","accession":"0001145197-22-000059","form_type":"8-K","ticker":"PODD","cik":"0001145197","company_name":"INSULET CORP","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.749855+00:00","generated_at":"2026-06-22T08:03:27.492615+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Insulet Q3 revenue $340.8M (+24% YoY) beat guidance; Omnipod 5 drives 42% US growth","bullets":["Revenue $340.8M, +23.7% YoY (+28.5% constant currency), above guidance of 17-20% constant currency.","US Omnipod revenue $238.1M (+42.4% YoY) on record new customer starts; International Omnipod $88.0M (-5.5%, +8.9% CC).","Adjusted EPS $0.45; GAAP net loss $(0.08)/share includes $36.8M charge for voluntary Omnipod DASH PDM correction.","Adjusted gross margin 66.1% (excl. PDM charge); GAAP gross margin 55.3%, down 1,320 bps.","Received CE Mark for Omnipod 5; expanded US indication to age 2; new basal-only pod for type 2 diabetes planned for 510(k)."],"urls":{"canonical":"https://secwatch.observer/filing/0001145197-22-000059","json":"https://secwatch.observer/filing/0001145197-22-000059.json","markdown":"https://secwatch.observer/filing/0001145197-22-000059.md","text":"https://secwatch.observer/filing/0001145197-22-000059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1145197/000114519722000059/0001145197-22-000059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1145197/000114519722000059/podd-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T08:03:27.492615+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4676fcbd98217bcfc94fe0fb5db5f46eae8941e5","claim":"INSULET CORP reported the three months ended September 30, 2022 results: revenue $340.8 million, net income Net loss of $5.2 million, or $(0.08) per diluted share, EPS $(0.08) per diluted share.","evidence_excerpt":"Omnipod ® brand of products, today announced financial results for the three months ended September 30, 2022. Third Quarter Financial Highlights: • Third quarter 2022 revenue of $340.8 million, up 23.7%, or 28.5% in constant currency 1 , compared to $275.6 million in the prior year, exceeds the guidance range of 17% to 20% in constant currency ◦ Total Omnipod revenue","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1145197/000114519722000059/0001145197-22-000059-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2022"},{"label":"Revenue","value":"$340.8 million"},{"label":"Net income","value":"Net loss of $5.2 million, or $(0.08) per diluted share"},{"label":"EPS","value":"$(0.08) per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}